Taken together, these findings suggest that, in European populations, DPP4 inhibitors are unlikely to have a detrimental effect on HF via DPP4 gene expression at the mRNA level; however, there is no evidence to support a causal role in other cardiovascular outcomes. This evidence concerns the gene DPP4 and hydrops fetalis.